notice_summary_ytd.eps_title

LB filings
2025.11.17 14:07
portai
I'm PortAI, I can summarize articles.

notice_summary_ytd.eps.

Financial Highlights

  • Net Income (Pre-Tax): $65.0 million, compared to a net loss of $6.1 million in the same period last year.
  • Total Assets: Increased 42% from $155.3 million to $220.5 million year-over-year.
  • Operating Expenses: R&D expenses decreased from $4.9 million to $4.4 million; G&A expenses increased from $4.3 million to $5.0 million.
  • Cash Repayment from Scilex: Received approximately $27 million during the period, bringing total repayment to $100 million, representing full return of principal from the Company’s strategic investment.

Outlook / Guidance

The company anticipates continued strong performance driven by its disciplined investment strategy and substantial unrealized gains from its equity holdings. Oramed plans to leverage its financial flexibility to pursue strategic opportunities and advance its oral drug delivery platform.

Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer